Cipla gets US FDA nod for generic heart drug

Pharmaceutical major Cipla said it has received US FDA approval to sell a generic version of heart drug Toprol by  Aralez Pharmaceuticals.

Toprol and its equivalents had US sales of approximately $464 million for the 12-month period ending Aug 2018, the company said.

That puts it among mid-sized drugs by sales, versus the $100 mln market size that most drugs enjoy.

Cipla’s Metoprolol tablets will be sold in 50mg, 100mg and 200mg doses.

The drug is a beta1-selective adrenoceptor blocking agent.

Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure and Angina Pectoris.

It is also used in heart failure for the treatment of stable, symptomatic heart failure of ischemic, hypertensive, or cardiomyopathic origin.